Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Primary fibromyalgia : clinical parameters in relation to serum procollagen type III aminoterminal peptide. / Jacobsen, S; Jensen, L T; Foldager, M; Danneskiold-Samsøe, B.

I: British Journal of Rheumatology, Bind 29, Nr. 3, 06.1990, s. 174-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Jacobsen, S, Jensen, LT, Foldager, M & Danneskiold-Samsøe, B 1990, 'Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide', British Journal of Rheumatology, bind 29, nr. 3, s. 174-7.

APA

Jacobsen, S., Jensen, L. T., Foldager, M., & Danneskiold-Samsøe, B. (1990). Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide. British Journal of Rheumatology, 29(3), 174-7.

Vancouver

Jacobsen S, Jensen LT, Foldager M, Danneskiold-Samsøe B. Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide. British Journal of Rheumatology. 1990 jun.;29(3):174-7.

Author

Jacobsen, S ; Jensen, L T ; Foldager, M ; Danneskiold-Samsøe, B. / Primary fibromyalgia : clinical parameters in relation to serum procollagen type III aminoterminal peptide. I: British Journal of Rheumatology. 1990 ; Bind 29, Nr. 3. s. 174-7.

Bibtex

@article{92dcc070978d440890fd73a7ece60361,
title = "Primary fibromyalgia: clinical parameters in relation to serum procollagen type III aminoterminal peptide",
abstract = "Serum concentrations of procollagen type III aminoterminal peptide have previously been reported to be low in some patients with primary fibromyalgia and the aim of this study was to determine if such patients differ clinically from primary fibromyalgia patients with normal levels of procollagen type III aminoterminal peptide. Subjective symptoms, tender points and dynamic muscle strength in 45 women with primary fibromyalgia were related to serum concentrations of procollagen type III aminoterminal peptide. Patients with low serum concentrations of procollagen type III aminoterminal peptide had more symptoms, a higher frequency of tender points and lesser quality of sleep compared to patients with normal serum concentrations of procollagen type III aminoterminal peptide (P less than 0.05). They also had a lower dynamic muscle strength (P less than 0.0005). We conclude that the serum concentrations of procollagen type III aminoterminal peptide of primary fibromyalgia patients are connected to the disease impact.",
keywords = "Adult, Aged, Female, Fibromyalgia, Humans, Middle Aged, Muscles, Pain, Peptide Fragments, Procollagen, Sleep Wake Disorders, Journal Article, Research Support, Non-U.S. Gov't",
author = "S Jacobsen and Jensen, {L T} and M Foldager and B Danneskiold-Sams{\o}e",
year = "1990",
month = jun,
language = "English",
volume = "29",
pages = "174--7",
journal = "British Journal of Rheumatology",
issn = "0263-7103",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Primary fibromyalgia

T2 - clinical parameters in relation to serum procollagen type III aminoterminal peptide

AU - Jacobsen, S

AU - Jensen, L T

AU - Foldager, M

AU - Danneskiold-Samsøe, B

PY - 1990/6

Y1 - 1990/6

N2 - Serum concentrations of procollagen type III aminoterminal peptide have previously been reported to be low in some patients with primary fibromyalgia and the aim of this study was to determine if such patients differ clinically from primary fibromyalgia patients with normal levels of procollagen type III aminoterminal peptide. Subjective symptoms, tender points and dynamic muscle strength in 45 women with primary fibromyalgia were related to serum concentrations of procollagen type III aminoterminal peptide. Patients with low serum concentrations of procollagen type III aminoterminal peptide had more symptoms, a higher frequency of tender points and lesser quality of sleep compared to patients with normal serum concentrations of procollagen type III aminoterminal peptide (P less than 0.05). They also had a lower dynamic muscle strength (P less than 0.0005). We conclude that the serum concentrations of procollagen type III aminoterminal peptide of primary fibromyalgia patients are connected to the disease impact.

AB - Serum concentrations of procollagen type III aminoterminal peptide have previously been reported to be low in some patients with primary fibromyalgia and the aim of this study was to determine if such patients differ clinically from primary fibromyalgia patients with normal levels of procollagen type III aminoterminal peptide. Subjective symptoms, tender points and dynamic muscle strength in 45 women with primary fibromyalgia were related to serum concentrations of procollagen type III aminoterminal peptide. Patients with low serum concentrations of procollagen type III aminoterminal peptide had more symptoms, a higher frequency of tender points and lesser quality of sleep compared to patients with normal serum concentrations of procollagen type III aminoterminal peptide (P less than 0.05). They also had a lower dynamic muscle strength (P less than 0.0005). We conclude that the serum concentrations of procollagen type III aminoterminal peptide of primary fibromyalgia patients are connected to the disease impact.

KW - Adult

KW - Aged

KW - Female

KW - Fibromyalgia

KW - Humans

KW - Middle Aged

KW - Muscles

KW - Pain

KW - Peptide Fragments

KW - Procollagen

KW - Sleep Wake Disorders

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

M3 - Journal article

C2 - 2357497

VL - 29

SP - 174

EP - 177

JO - British Journal of Rheumatology

JF - British Journal of Rheumatology

SN - 0263-7103

IS - 3

ER -

ID: 168533529